Hannah Brendan's Form 4 filing
Quince Therapeutics, Inc. (QNCX) · filed Aug 21, 2024
- Accession no.
- 0001415889-24-021869
- Filed
- Aug 21, 2024
- Trade date
- Aug 19-21, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 0 derivative transactions. Open-market purchases total $24.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hannah BrendanCIK 0001929422 | Officer (CHIEF BUSINESS OFFICER AND COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 19, 2024 | Common Stock | PPurchaseAcquired | +2,155 | $0.58 | +$1,249.9 | 259,771 | Direct | |
| Aug 20, 2024 | Common Stock | PPurchaseAcquired | +2,500 | $0.61 | +$1,525 | 262,271 | Direct | |
| Aug 20, 2024 | Common Stock | PPurchaseAcquired | +3,424 | $0.60 | +$2,054.4 | 265,695 | Direct | |
| Aug 21, 2024 | Common Stock | PPurchaseAcquired | +2,280 | $0.61 | +$1,390.8 | 267,975 | Direct | |
| Aug 21, 2024 | Common Stock | PPurchaseAcquired | +5,000 | $0.62 | +$3,100 | 272,975 | Direct | |
| Aug 21, 2024 | Common Stock | PPurchaseAcquired | +23,565 | $0.63 | +$14,845.95 | 296,540 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.